Terence Flynn
Stock Analyst at Morgan Stanley
(4.31)
# 401
Out of 5,090 analysts
221
Total ratings
60.18%
Success rate
13.02%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $516 → $564 | $455.48 | +23.83% | 3 | Dec 5, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $92 → $120 | $99.72 | +20.34% | 19 | Dec 2, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,171 → $1,290 | $1,010.31 | +27.68% | 23 | Nov 24, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $54 → $26 | $9.55 | +172.25% | 4 | Nov 18, 2025 | |
| OGN Organon & Co. | Maintains: Equal-Weight | $10 → $9 | $7.14 | +26.05% | 11 | Nov 11, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $333 → $329 | $329.89 | -0.27% | 10 | Nov 5, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $178 → $190 | $201.93 | -5.91% | 25 | Oct 15, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Equal-Weight | $16 → $15 | $18.09 | -17.08% | 6 | Oct 14, 2025 | |
| PFE Pfizer | Maintains: Equal-Weight | $33 → $32 | $26.03 | +22.94% | 19 | Oct 10, 2025 | |
| RPRX Royalty Pharma | Maintains: Overweight | $55 → $54 | $39.73 | +35.92% | 13 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $133 → $131 | $96.25 | +36.10% | 5 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $328 → $435 | $489.31 | -11.10% | 11 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $22 | $11.12 | +97.84% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $23 | $25.45 | -9.63% | 8 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $255 | $226.08 | +12.79% | 18 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $34 | $52.15 | -34.80% | 11 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $12.79 | -14.00% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $56.88 | -43.74% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $9.61 | +14.46% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $118 | $34.56 | +241.44% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $2.67 | +199.63% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $181.30 | +140.49% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $458.12 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.42 | - | 1 | Jul 21, 2017 |
Vertex Pharmaceuticals
Dec 5, 2025
Maintains: Overweight
Price Target: $516 → $564
Current: $455.48
Upside: +23.83%
Merck & Co.
Dec 2, 2025
Maintains: Buy
Price Target: $92 → $120
Current: $99.72
Upside: +20.34%
Eli Lilly and Company
Nov 24, 2025
Maintains: Overweight
Price Target: $1,171 → $1,290
Current: $1,010.31
Upside: +27.68%
Biohaven
Nov 18, 2025
Maintains: Overweight
Price Target: $54 → $26
Current: $9.55
Upside: +172.25%
Organon & Co.
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $10 → $9
Current: $7.14
Upside: +26.05%
Amgen
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $333 → $329
Current: $329.89
Upside: -0.27%
Johnson & Johnson
Oct 15, 2025
Maintains: Equal-Weight
Price Target: $178 → $190
Current: $201.93
Upside: -5.91%
Nurix Therapeutics
Oct 14, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $18.09
Upside: -17.08%
Pfizer
Oct 10, 2025
Maintains: Equal-Weight
Price Target: $33 → $32
Current: $26.03
Upside: +22.94%
Royalty Pharma
Oct 10, 2025
Maintains: Overweight
Price Target: $55 → $54
Current: $39.73
Upside: +35.92%
Oct 10, 2025
Maintains: Overweight
Price Target: $133 → $131
Current: $96.25
Upside: +36.10%
Oct 10, 2025
Maintains: Equal-Weight
Price Target: $328 → $435
Current: $489.31
Upside: -11.10%
Aug 15, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $11.12
Upside: +97.84%
Aug 7, 2025
Maintains: Overweight
Price Target: $22 → $23
Current: $25.45
Upside: -9.63%
Aug 1, 2025
Maintains: Overweight
Price Target: $250 → $255
Current: $226.08
Upside: +12.79%
Jul 10, 2025
Maintains: Underweight
Price Target: $36 → $34
Current: $52.15
Upside: -34.80%
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $12.79
Upside: -14.00%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $56.88
Upside: -43.74%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $9.61
Upside: +14.46%
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $34.56
Upside: +241.44%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $2.67
Upside: +199.63%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $181.30
Upside: +140.49%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $458.12
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $8.42
Upside: -